← Back to Patent Explorer
US5225404A Expired / Lapsed US ⏱️ 0.0 years remaining

Methods of treating colon tumors with tumor-inhibiting camptothecin compounds

Assignee: Christus Stehlin Foundation for Cancer Research
•
Filing: 1989-11-06
•
Granted: 1993-07-06
•
Expires: 2009-11-06
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention provides methods of treating malignant colon and colo-rectal cancer in mammals, by reducing or inhibiting or retarding such colon cancer tumors in mammals. These methods employ the administration of a tumor-inhibiting or reducing camptothecin compound, e.g., 9-amino-20(RS)-camptothecin, 10,11-methylenedioxy-20(RS)-camptothecin, and the sodium salt of 10,11-methylenedioxy-20(RS)-camptothecin, or a combination thereof. Also provided are pharmaceutical formulations.

Inventors

  • 👤 Beppino C. Giovannella
  • 👤 Leroy F. Liu
  • 👤 Milan Potmesil
  • 👤 Monroe C. Wall
  • 👤 Robert F. Silber
  • 👤 Mansukh C. Wani

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 03:01
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47

Claims Analysis

Total Claims: 36
Claim 1
Independent Claim 52 words
A method of treating malignant colon tumors in a mammal in need of such treatment which comprises administering to said mammal an effective amount for treating said tumor of a tumor inhibiting camptothecin compound selected from the group consisting of 9-amino-20(RS)-camptothecin, 10,11-methylenedioxy-20(RS)-camptothecin and the sodium salt of 10,11-methylenedioxy-20(RS)-camptothecin, or a combination thereof.
Claim 2
Independent Claim 52 words
A method of treating malignant colon tumors in a mammal in need of such treatment which comprises administering to said mammal an effective amount for treating said tumor of a tumor inhibiting camptothecin compound selected from the group consisting of 9-amino-20(RS)-camptothecin, 10,11-methylenedioxy-20(RS)-camptothecin and the sodium salt of 10,11-methylenedioxy-20(RS)-camptothecin, or a combination thereof.
Claim 3
Dependent Claim 13 words
The method according to claim 1 wherein said colon tumors comprise colo-rectal tumors.
Claim 4
Dependent Claim 14 words
The method according to claim 1 wherein said tumor inhibiting camptothecin compound comprises 9-amino-20(RS)-camptothecin.
Claim 5
Dependent Claim 14 words
The method according to claim 1 wherein said tumor inhibiting camptothecin compound comprises 10,11-methylenedioxy-20(RS)-camptothecin.
Claim 6
Dependent Claim 17 words
The method according to claim 1 wherein said tumor inhibiting compound comprises the sodium salt of 10,11-methylenedioxy-20(RS)-camptothecin.
Claim 7
Dependent Claim 31 words
The method according to claim 1 wherein said effective amount comprises from about 2 mg/per kg of body weight per week to about 35 mg/per kg of body weight per week.
Claim 8
Dependent Claim 47 words
The method according to claim 6 which comprises dividing said effective amount into doses to be administered more than once a week but wherein the total dosage administered per week is from about 2 mg/per kg of body weight to about 35 mg/per kg of body weight.
Claim 9
Dependent Claim 20 words
The method according to claim 6 which comprises administering said effective amount in divided doses about two times per week.
Claim 10
Dependent Claim 17 words
The method according to claim 1 which comprises parenteral administering said tumor inhibiting camptothecin compound said mammal.
Claim 11
Dependent Claim 19 words
The method according to claim 9 wherein said parenteral administration of the tumor inhibiting camptothecin compound comprises subcutaneous injection.
Claim 12
Independent Claim 34 words
A method for retarding a colo-rectal tumor in a mammal in need of such treatment which comprises administering to said mammal an effective amount for retarding said tumor of a colo-rectal inhibiting camptothecin compound.
Claim 13
Independent Claim 34 words
A method for retarding a colo-rectal tumor in a mammal in need of such treatment which comprises administering to said mammal an effective amount for retarding said tumor of a colo-rectal inhibiting camptothecin compound.
Claim 14
Dependent Claim 39 words
A pharmaceutical formulation comprising an effective amount for inhibiting the growth of a colon tumor of a colon tumor-inhibiting camptothecin compound selected from the group consisting of 9-amino-20(RS)-camptothecin, 10,11-methylenedioxy-20(RS)-camptothecin and the sodium salt of 10,11-methylenedioxy-20(RS)-camptothecin, or a combination thereof.
Claim 15
Dependent Claim 39 words
A pharmaceutical formulation comprising an effective amount for inhibiting the growth of a colon tumor of a colon tumor-inhibiting camptothecin compound selected from the group consisting of 9-amino-20(RS)-camptothecin, 10,11-methylenedioxy-20(RS)-camptothecin and the sodium salt of 10,11-methylenedioxy-20(RS)-camptothecin, or a combination thereof.
Claim 16
Dependent Claim 12 words
The pharmaceutical formulation according to claim 12 wherein said compound comprises 9-amino-20(RS)-camptothecin.
Claim 17
Dependent Claim 20 words
The pharmaceutical formulation according to claim 12 comprising from about 100 mg to about 500 mg of said camptothecin compound.
Claim 18
Dependent Claim 12 words
The pharmaceutical formulation according to claim 12 comprising a parenteral dosage form.
Claim 19
Dependent Claim 23 words
The pharmaceutical formulation according to claim 12 comprising an oral dosage form selected from the group consisting of a tablet and a capsule.
Claim 20
Independent Claim 52 words
A method of treating malignant colon tumors in a mammal in need of such treatment which comprises administering to said mammal an effective amount for treating said tumor of a tumor inhibiting camptothecin compound selected from the group consisting of 9-amino-20(S)-camptothecin, 10,11-methylenedioxy-20(S)-camptothecin and the sodium salt of 10,11-methylenedioxy-20(S)-camptothecin, or a combination thereof.
Claim 21
Independent Claim 52 words
A method of treating malignant colon tumors in a mammal in need of such treatment which comprises administering to said mammal an effective amount for treating said tumor of a tumor inhibiting camptothecin compound selected from the group consisting of 9-amino-20(S)-camptothecin, 10,11-methylenedioxy-20(S)-camptothecin and the sodium salt of 10,11-methylenedioxy-20(S)-camptothecin, or a combination thereof.
Claim 22
Dependent Claim 13 words
The method according to claim 17 wherein said colon tumors comprise colo-rectal tumors.
Claim 23
Dependent Claim 14 words
The method according to claim 17 wherein said tumor inhibiting camptothecin compound comprises 9-amino-20(S)-camptothecin.
Claim 24
Dependent Claim 14 words
The method according to claim 17 wherein said tumor inhibiting camptothecin compound comprises 10,11-methylenedioxy-20(S)-camptothecin.
Claim 25
Dependent Claim 17 words
The method according to claim 17 wherein said tumor inhibiting compound comprises the sodium salt of 10,11-methylenedioxy-20(S)-camptothecin.
Claim 26
Dependent Claim 31 words
The method according to claim 17 wherein said effective amount comprises from about 2 mg/per kg of body weight per week to about 35 mg/per kg of body weight per week.
Claim 27
Dependent Claim 47 words
The method according to claim 22 which comprises dividing said effective amount into doses to be administered more than once a week but wherein the total dosage administered per week is from about 2 mg/per kg of body weight to about 35 mg/per kg of body weight.
Claim 28
Dependent Claim 19 words
The method according to claim 22 which comprises administering said effective amount in divided doses two times per week.
Claim 29
Dependent Claim 18 words
The method according to claim 17 which comprises parenterally administering said tumor inhibiting camptothecin compound to said mammal.
Claim 30
Dependent Claim 13 words
The method according to claim 25 wherein said parenteral administration comprises subcutaneous injection.
Claim 31
Dependent Claim 39 words
A pharmaceutical formulation comprises an effective amount for inhibiting the growth of a colon tumor of a colon tumor-inhibiting camptothecin compound selected from the group consisting of 9-amino-20(S)-camptothecin, 10,11-methylenedioxy-20(S)-camptothecin and the sodium salt of 10,11-methylenedioxy-20(S)-camptothecin, or a combination thereof.
Claim 32
Dependent Claim 39 words
A pharmaceutical formulation comprises an effective amount for inhibiting the growth of a colon tumor of a colon tumor-inhibiting camptothecin compound selected from the group consisting of 9-amino-20(S)-camptothecin, 10,11-methylenedioxy-20(S)-camptothecin and the sodium salt of 10,11-methylenedioxy-20(S)-camptothecin, or a combination thereof.
Claim 33
Dependent Claim 12 words
The pharmaceutical formulation according to claim 27 wherein said compound comprises 9-amino-20(S)-camptothecin.
Claim 34
Dependent Claim 20 words
The pharmaceutical formulation according to claim 27 comprising from about 100 mg to about 500 mg of said camptothecin compound.
Claim 35
Dependent Claim 12 words
The pharmaceutical formulation according to claim 27 comprising a parenteral dosage form.
Claim 36
Dependent Claim 23 words
The pharmaceutical formulation according to claim 27 comprising an oral dosage form selected from the group consisting of a tablet and a capsule.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-07-05 1997-01-04 1997-07-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-07-05 2001-01-04 2001-07-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-07-05 2005-01-04 2005-07-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag